NO323783B1 - Anvendelse av en forbindelse for fremstilling av et medikament - Google Patents
Anvendelse av en forbindelse for fremstilling av et medikament Download PDFInfo
- Publication number
- NO323783B1 NO323783B1 NO20023892A NO20023892A NO323783B1 NO 323783 B1 NO323783 B1 NO 323783B1 NO 20023892 A NO20023892 A NO 20023892A NO 20023892 A NO20023892 A NO 20023892A NO 323783 B1 NO323783 B1 NO 323783B1
- Authority
- NO
- Norway
- Prior art keywords
- compound
- positions
- group
- iodine
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- 150000002367 halogens Chemical class 0.000 claims abstract description 4
- OIVUHPTVQVCONM-UHFFFAOYSA-N 6-bromo-4-methyl-1h-indazole Chemical compound CC1=CC(Br)=CC2=C1C=NN2 OIVUHPTVQVCONM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims abstract description 3
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- NXOVZLREWXNIDP-UHFFFAOYSA-N 7h-pyrazino[2,3-c]carbazole Chemical class N1=CC=NC2=C3C4=CC=CC=C4NC3=CC=C21 NXOVZLREWXNIDP-UHFFFAOYSA-N 0.000 claims description 3
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 claims description 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- VMWJCFLUSKZZDX-UHFFFAOYSA-N n,n-dimethylmethanamine Chemical group [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 6
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 5
- 102000003996 Interferon-beta Human genes 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229960001388 interferon-beta Drugs 0.000 description 4
- 231100000706 no observed effect level Toxicity 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 3
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- ZUNBGWZFZVZJHX-UHFFFAOYSA-N 2-(2,3-dimethyl-6h-indolo[2,3-b]quinoxalin-1-yl)-n,n-dimethylethanamine Chemical compound N1C2=NC3=CC=CC=C3C2=NC2=C1C=C(C)C(C)=C2CCN(C)C ZUNBGWZFZVZJHX-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0000537A SE516067C2 (sv) | 2000-02-18 | 2000-02-18 | Användning av en förening för framställning av ett läkemedel |
| PCT/SE2001/000326 WO2001060371A1 (en) | 2000-02-18 | 2001-02-16 | Use of a compound for preparing a drug |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20023892D0 NO20023892D0 (no) | 2002-08-16 |
| NO20023892L NO20023892L (no) | 2002-08-16 |
| NO323783B1 true NO323783B1 (no) | 2007-07-09 |
Family
ID=20278504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023892A NO323783B1 (no) | 2000-02-18 | 2002-08-16 | Anvendelse av en forbindelse for fremstilling av et medikament |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1261344B1 (de) |
| JP (1) | JP2003522792A (de) |
| CN (1) | CN1192777C (de) |
| AT (1) | ATE269083T1 (de) |
| AU (2) | AU2001236266B2 (de) |
| CA (1) | CA2400236C (de) |
| DE (1) | DE60103857T2 (de) |
| ES (1) | ES2222981T3 (de) |
| HU (1) | HUP0204547A3 (de) |
| NO (1) | NO323783B1 (de) |
| RU (1) | RU2266117C2 (de) |
| SE (1) | SE516067C2 (de) |
| WO (1) | WO2001060371A1 (de) |
| ZA (1) | ZA200206733B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE527639C2 (sv) * | 2004-06-17 | 2006-05-02 | Oxypharma Ab | Alkylsubstituerade indolokinoxaliner |
| EP2128160B1 (de) | 2008-04-30 | 2010-07-14 | Universität Duisburg-Essen | Indol[2,3-b]-, Inden[1,2-b]- und Inden[2,1-b]pyrido[2,3-f] Quinoxalin-3-Carboxylsäuren und Ester, Verfahren zu ihrer Herstellung und ihre Verwendung als Antivirus- und Antitumormittel |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8600260D0 (sv) * | 1986-01-21 | 1986-01-21 | Lundblad Leif | Substituerade indolokinoxaliner |
-
2000
- 2000-02-18 SE SE0000537A patent/SE516067C2/sv not_active IP Right Cessation
-
2001
- 2001-02-16 WO PCT/SE2001/000326 patent/WO2001060371A1/en active IP Right Grant
- 2001-02-16 RU RU2002124771/15A patent/RU2266117C2/ru active
- 2001-02-16 CA CA002400236A patent/CA2400236C/en not_active Expired - Fee Related
- 2001-02-16 AU AU2001236266A patent/AU2001236266B2/en not_active Ceased
- 2001-02-16 AT AT01908522T patent/ATE269083T1/de not_active IP Right Cessation
- 2001-02-16 EP EP01908522A patent/EP1261344B1/de not_active Expired - Lifetime
- 2001-02-16 ES ES01908522T patent/ES2222981T3/es not_active Expired - Lifetime
- 2001-02-16 DE DE60103857T patent/DE60103857T2/de not_active Expired - Fee Related
- 2001-02-16 CN CNB018052045A patent/CN1192777C/zh not_active Expired - Fee Related
- 2001-02-16 HU HU0204547A patent/HUP0204547A3/hu unknown
- 2001-02-16 AU AU3626601A patent/AU3626601A/xx active Pending
- 2001-02-16 JP JP2001559467A patent/JP2003522792A/ja active Pending
-
2002
- 2002-08-16 NO NO20023892A patent/NO323783B1/no not_active IP Right Cessation
- 2002-08-22 ZA ZA200206733A patent/ZA200206733B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1261344A1 (de) | 2002-12-04 |
| CN1404393A (zh) | 2003-03-19 |
| CA2400236C (en) | 2009-09-22 |
| JP2003522792A (ja) | 2003-07-29 |
| CA2400236A1 (en) | 2001-08-23 |
| SE0000537L (sv) | 2001-08-19 |
| NO20023892D0 (no) | 2002-08-16 |
| ATE269083T1 (de) | 2004-07-15 |
| DE60103857T2 (de) | 2005-07-14 |
| AU3626601A (en) | 2001-08-27 |
| AU2001236266B2 (en) | 2005-03-17 |
| EP1261344B1 (de) | 2004-06-16 |
| CN1192777C (zh) | 2005-03-16 |
| SE516067C2 (sv) | 2001-11-12 |
| RU2002124771A (ru) | 2004-03-10 |
| RU2266117C2 (ru) | 2005-12-20 |
| HUP0204547A2 (hu) | 2003-04-28 |
| SE0000537D0 (sv) | 2000-02-18 |
| DE60103857D1 (de) | 2004-07-22 |
| HUP0204547A3 (en) | 2006-01-30 |
| ZA200206733B (en) | 2003-08-22 |
| ES2222981T3 (es) | 2005-02-16 |
| WO2001060371A1 (en) | 2001-08-23 |
| NO20023892L (no) | 2002-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2339934C (en) | Medicine for multiple sclerosis | |
| JPS5852225A (ja) | 脱髄疾患治療剤 | |
| RU2010116859A (ru) | ПРИМЕНЕНИЕ 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА В ЛЕЧЕНИИ РАССЕЯННОГО СКЛЕРОЗА И АУТОИММУННОГО МИЕЛИТА | |
| Mamo | Treatment of Behçet disease with chlorambucil: A follow-up report | |
| US6903100B2 (en) | Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system | |
| EP2523668A1 (de) | Behandlung multipler sklerose | |
| NO323783B1 (no) | Anvendelse av en forbindelse for fremstilling av et medikament | |
| WO2001045715A3 (en) | Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain | |
| Wach et al. | Treatment of severe localized scleroderma by plasmapheresis report of three cases | |
| US5434142A (en) | Method of treatment for muscular dystrophy | |
| GB9930077D0 (en) | Medicaments | |
| US6333327B2 (en) | Method for the treatment of Multiple Sclerosis | |
| JP2019533731A (ja) | Ｃｂｄとコパキソンの併用療法 | |
| KR20160096804A (ko) | 조루증 예방 및 치료용 한약재 조성물 | |
| KR102320841B1 (ko) | 니클로사마이드를 포함하는 관절염 예방 및 치료용 조성물 | |
| Ell et al. | Acquired pendular nystagmus: characteristics, pathophysiology and pharmacological modification | |
| JPH0656661A (ja) | 抗白内障剤 | |
| GB9930085D0 (en) | Medicaments | |
| Öztürk et al. | Quetiapine and risperidone-associated priapism: a case report | |
| Zeller et al. | Intravenous interferon-alpha treatment of mixed cryoglobulinemia associated with chronic hepatitis C virus infection | |
| JP2000159677A (ja) | ヒアルロン酸を有効成分とする異所性石灰化抑制剤 | |
| Tennant Jr | (−)-α-Acetylmethadol for treatment of chronic pain patients who abuse opioids | |
| WO2015028673A1 (en) | Cav3 CHANNEL BLOCKING AGENT FOR PAIN TREATMENT | |
| KR20150084862A (ko) | 면역조절용 사퀴나비어-no | |
| Brown et al. | The effect of COX-2 specific inhibitors on fracture healing in the adult rat femur |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |